UNIVERSITY RESEARCH TO
PIONEER NEXT GENERATION OF
SKIN TREATMENTS
IP based on translational research led by Dr Catherine
O'Neill and Professor Andrew McBain at the University
has been transferred into a new company. The venture,
Skinbiotix limited, is being supported by OptiBiotix Health
plc (AIM: OPTI). OptiBiotix is a leading life sciences business
developing products to tackle obesity, high cholesterol and
diabetes on a global scale. The agreement was negotiated
on behalf of the University by UMIP.
The images show human
skin which has been
stained with a green dye to
visualise a protein, critical to
skins function as a barrier
between the body and the
environment. The level
of this protein increases
dramatically following
treatment with a particular
bacterium (compare
'untreated' with 'treated').
Untreated
UMIP HIGHLIGHTS
